Two phase III trials are underway for BTK inhibitors in PPMS and one phase III trial in non-relapsing SPMS, ClinicalTrials.gov identifiers: NCT04544449, NCT04458051 and NCT04411641. The gene discussed is BTK; the disease is primary progressive multiple sclerosis.